NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022-Reference-Cited by-同舟云学术

NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022

Published:2022-04 Issue:4 Volume:20 Page:322-334
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Hoppe Richard T.¹,Advani Ranjana H.¹,Ai Weiyun Z.²,Ambinder Richard F.³,Armand Philippe⁴,Bello Celeste M.⁵,Benitez Cecil M.⁶,Chen Weina⁷,Dabaja Bouthaina⁸,Daly Megan E.⁹,Gordon Leo I.¹⁰,Hansen Neil¹¹,Herrera Alex F.¹²,Hochberg Ephraim P.¹³,Johnston Patrick B.¹⁴,Kaminski Mark S.¹⁵,Kelsey Christopher R.¹⁶,Kenkre Vaishalee P.¹⁷,Khan Nadia¹⁸,Lynch Ryan C.¹⁹,Maddocks Kami²⁰,McConathy Jonathan²¹,Metzger Monika²²,Morgan David²³,Mulroney Carolyn²⁴,Pullarkat Sheeja T.⁶,Rabinovitch Rachel²⁵,Rosenspire Karen C.²⁶,Seropian Stuart²⁷,Tao Randa²⁸,Torka Pallawi²⁹,Winter Jane N.¹⁰,Yahalom Joachim³⁰,Yang Joanna C.³¹,Burns Jennifer L.³²,Campbell Mallory³²,Sundar Hema³²

Affiliation:

1. 1Stanford Cancer Institute;

2. 2UCSF Helen Diller Family Comprehensive Cancer Center;

3. 3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

4. 4Dana-Farber/Brigham and Women’s Cancer Center;

5. 5Moffitt Cancer Center;

6. 6UCLA Jonsson Comprehensive Cancer Center;

7. 7UT Southwestern Simmons Comprehensive Cancer Center;

8. 8The University of Texas MD Anderson Cancer Center;

9. 9UC Davis Comprehensive Cancer Center;

10. 10Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

11. 11Fred & Pamela Buffett Cancer Center;

12. 12City of Hope National Medical Center;

13. 13Massachusetts General Hospital Cancer Center;

14. 14Mayo Clinic Cancer Center;

15. 15University of Michigan Rogel Cancer Center;

16. 16Duke Cancer Institute;

17. 17University of Wisconsin Carbone Cancer Center;

18. 18Fox Chase Cancer Center;

19. 19Fred Hutchinson Cancer Research Center/University of Washington;

20. 20The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

21. 21O'Neal Comprehensive Cancer Center at UAB;

22. 22St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center;

23. 23Vanderbilt-Ingram Cancer Center;

24. 24UC San Diego Moores Cancer Center;

25. 25University of Colorado Cancer Center;

26. 26Abramson Cancer Center at the University of Pennsylvania;

27. 27Yale Cancer Center/Smilow Cancer Hospital;

28. 28Huntsman Cancer Institute at the University of Utah;

29. 29Roswell Park Comprehensive Cancer Center;

30. 30Memorial Sloan Kettering Cancer Center;

31. 31Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; and

32. 32National Comprehensive Cancer Network.

Abstract

Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte–predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment options that overriding treatment considerations often relate to long-term toxicity. These NCCN Guidelines Insights discuss the recent updates to the NCCN Guidelines for HL focusing on (1) radiation therapy dose constraints in the management of patients with HL, and (2) the management of advanced-stage and relapsed or refractory cHL.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/20/4/article-p322.xml

Reference146 articles.

1. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial;Straus;Lancet Haematol,2021

2. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial;Moskowitz;Lancet,2015

3. Brentuximab vedotin and nivolumab for relapsed or refractory classic Hodgkin lymphoma: long-term follow-up results from the single-arm phase 1/2 study [abstract];Moskowitz;Blood,2019

4. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study;Straus;Blood,2020

5. Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma;Gutierrez;OncoTargets Ther,2014

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma;JCO Oncology Practice;2024-09-12

2. At the Cutting Edge: Novel Agents in Hodgkin Lymphoma and the Evolving Role of Radiation Therapy;International Journal of Radiation Oncology*Biology*Physics;2024-09

3. A Radiation-Free Approach Based on the Whole-Body MRI Has Shown a High Level of Accuracy in the Follow-Up of Lymphoma Patients—A Single Center Retrospective Study;Journal of Clinical Medicine;2024-06-21

4. Expression and prognostic impact of CD73 in classical Hodgkin lymphoma;2024-06-17

5. Topological importance of CD8 + T-cell enrichment in the tumor microenvironment of classic Hodgkin lymphoma;2024-06-10